Izun Pharmaceuticals Corporation, a clinical stage company focused on developing high efficacy products based on compounds derived from botanical sources, has appointed Jack Talley as its chief executive officer.

Mr. Talley brings over 30 years of relevant experience in the pharmaceutical industry, 15 of which were as chief executive in emerging pharmaceutical companies. Most recently, Mr. Talley was chief executive and president of Alissa Pharma, a company focusing on radioimmunotherapy utilizing novel targeted antibodies in the treatment of solid tumors. Prior to that he was the chief executive and president of EpiCept where he oversaw the establishment of EpiCept as a public company.

Bill Levine, the founder and previous chief executive officer of Izun, who has now assumed the role of executive chairman, said, “Jack brings invaluable expertise in both drug development and product commercialization to Izun. His leadership skills, breadth of knowledge of the industry, commercialization experience, proven interaction with regulatory bodies as well as successes in capital raising will surely be a tremendous asset to Izun.”

“The company has an exciting portfolio of pipeline products that are poised to deliver substantial benefits to patients and therefore shareholder value,” said Mr. Talley. “Izun’s unique skills can harness the power of botanical products coupled with a potentially favorable regulatory pathway is particularly attractive. The ongoing clinical programs are expected to deliver near term milestones that will fuel growth for the Company at this transformative stage.”